insights_auto
Why is PTCT up 3.38%?
Dive Deeperchevron_right
PTCT:NASDAQ
PTC Therapeutics, Inc.
$61.24
arrow_upward
+3.38%(+2.00) 1D
Oct 19, 2:24:06 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PTCT...
Open
$60.13
High
$61.51
Low
$59.35
Mkt. cap
5.11B
Avg. vol.
1.21M
Volume
371.80K
52-wk high
$90.86
52-wk low
$58.80
EPS
-$0.56
Beta
0.49
Shares outstanding
83.46M
No. of employees
991
Open
$60.13
High
$61.51
Low
$59.35
Mkt. cap
5.11B
Avg. vol.
1.21M
Volume
371.80K
52-wk high
$90.86
52-wk low
$58.80
EPS
-$0.56
Beta
0.49
Shares outstanding
83.46M
No. of employees
991
News stories
From web sources and news partners
ChartMill
·
32 minutes ago
Most Active S&P 500 Stocks on Oct. 19
KuCoin
·
50 minutes ago
The Dow finished last week up 0.7%. Most of the stock market
TradingView
·
1 hour ago
Midday Pulse: S&P 500 top intraday gainers
Crypto Briefing
·
41 minutes ago
Chip stocks hit lowest level against the S&P 500 since April 2026
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorBiotechnology
Websiteptcbio.com